McDaniel Terry & Co’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$508K Buy
3,325
+156
+5% +$23.9K 0.04% 63
2025
Q4
$437K Sell
3,169
-8
-0.3% -$1.05K 0.04% 62
2025
Q3
$407K Sell
3,177
-323
-9% -$39.4K 0.03% 74
2025
Q2
$424K Sell
3,500
-395
-10% -$44.5K 0.03% 69
2025
Q1
$434K Sell
3,895
-45
-1% -$4.79K 0.04% 72
2024
Q4
$383K Sell
3,940
-2,250
-36% -$240K 0.03% 75
2024
Q3
$712K Buy
6,190
+370
+6% +$42K 0.06% 57
2024
Q2
$620K Sell
5,820
-164
-3% -$16.5K 0.05% 59
2024
Q1
$579K Sell
5,984
-5,527
-48% -$567K 0.05% 64
2023
Q4
$1.16M Hold
11,511
0.11% 49
2023
Q3
$1.17M Hold
11,511
0.12% 48
2023
Q2
$1.16M Sell
11,511
-12
-0.1% -$1.2K 0.12% 46
2023
Q1
$1.06M Sell
11,523
-175
-1% -$15.3K 0.12% 42
2022
Q4
$1.06M Sell
11,698
-590
-5% -$49.7K 0.12% 44
2022
Q3
$934K Sell
12,288
-473
-4% -$39.2K 0.12% 43
2022
Q2
$1.08M Sell
12,761
-5,861
-31% -$514K 0.13% 41
2022
Q1
$1.63M Sell
18,622
-150,080
-89% -$13M 0.18% 39
2021
Q4
$14.8M Sell
168,702
-43,773
-21% -$3.63M 1.48% 29
2021
Q3
$17.4M Buy
212,475
+6,455
+3% +$581K 2.03% 24
2021
Q2
$18.8M Buy
206,020
+2,861
+1% +$255K 2.17% 21
2021
Q1
$17.4M Buy
203,159
+2,090
+1% +$188K 2.13% 23
2020
Q4
$19M Buy
201,069
+3,981
+2% +$348K 2.41% 22
2020
Q3
$17.1M Buy
197,088
+934
+0.5% +$80.9K 2.43% 20
2020
Q2
$17.1M Sell
196,154
-5,066
-3% -$437K 2.61% 17
2020
Q1
$16.6M Buy
201,220
+6,101
+3% +$544K 3.05% 15
2019
Q4
$18.5M Sell
195,119
-1,744
-0.9% -$156K 2.76% 20
2019
Q3
$17.1M Sell
196,863
-2,395
-1% -$215K 2.75% 21
2019
Q2
$18.2M Sell
199,258
-21,587
-10% -$1.83M 3.02% 18
2019
Q1
$19M Buy
220,845
+841
+0.4% +$67.5K 3.26% 16
2018
Q4
$16.9M Sell
220,004
-749
-0.3% -$58.3K 3.28% 15
2018
Q3
$17M Buy
220,753
+756
+0.3% +$55.9K 2.88% 21
2018
Q2
$14.9M Buy
219,997
+2,252
+1% +$155K 2.74% 21
2018
Q1
$15.8M Sell
217,745
-495
-0.2% -$37.7K 2.88% 20
2017
Q4
$16.4M Sell
218,240
-624
-0.3% -$47.1K 2.9% 20
2017
Q3
$16.8M Sell
218,864
-6,194
-3% -$468K 3.18% 20
2017
Q2
$16.8M Buy
225,058
+396
+0.2% +$28.1K 3.27% 20
2017
Q1
$15M Buy
224,662
+8,383
+4% +$559K 2.93% 22
2016
Q4
$14.1M Buy
216,279
+163
+0.1% +$10.6K 2.93% 22
2016
Q3
$15.3M Buy
216,116
+1,716
+0.8% +$125K 3.27% 18
2016
Q2
$15.9M Buy
214,400
+3,674
+2% +$254K 3.56% 16
2016
Q1
$13.7M Buy
210,726
+9,578
+5% +$652K 3.22% 23
2015
Q4
$15.5M Sell
201,148
-954
-0.5% -$75.8K 4.04% 14
2015
Q3
$16.6M Buy
202,102
+2,511
+1% +$223K 4.64% 8
2015
Q2
$17.6M Buy
199,591
+3,731
+2% +$342K 4.43% 7
2015
Q1
$17.3M Buy
195,860
+1,225
+0.6% +$109K 4.23% 10
2014
Q4
$16.2M Buy
194,635
+1,913
+1% +$159K 3.82% 14
2014
Q3
$16.3M Sell
192,722
-2,651
-1% -$214K 3.89% 12
2014
Q2
$15.8M Buy
195,373
+1,682
+0.9% +$132K 3.77% 13
2014
Q1
$14.8M Buy
193,691
+1,280
+0.7% +$93.3K 3.75% 13
2013
Q4
$13.9M Buy
192,411
+11,559
+6% +$804K 3.5% 18
2013
Q3
$12.4M Buy
180,852
+2,806
+2% +$186K 3.41% 15
2013
Q2
$11.3M Buy
+178,046
New +$11.6M 3.35% 13

Other funds holding NVS

McDaniel Terry & Co's NVS Position: Q1 2026 in Review

McDaniel Terry & Co increased its Novartis (NVS) stake by 4.9% in Q1 2026, buying an estimated $23.9K and bringing the position to 3,325 shares worth $508K. The position accounts for 0.04% of the portfolio, ranked #63.

McDaniel Terry & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $19M in Q1 2019. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • McDaniel Terry & Co held 3,325 shares of Novartis worth $508K as of Q1 2026.
  • McDaniel Terry & Co bought 156 Novartis shares in Q1 2026, an estimated $23.9K.
  • Novartis made up 0.04% of McDaniel Terry & Co's portfolio in Q1 2026, its #63 holding.
  • McDaniel Terry & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • McDaniel Terry & Co's Novartis position peaked at $19M in Q1 2019.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on McDaniel Terry & Co's 13F filing for Q1 2026, filed 5 May 2026.